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DruQuaR
Human beings live in a co-evolutionary association with microorganisms. The collection of these microorganisms
is termed the microbiome. Bacteria are able to communicate with each other by quorum sensing molecules. An
important group of these molecules are the oligopeptides, mainly produced by Gram-positive bacteria. These
quorum sensing peptides (QSP) are able to interact with human eukaryotic cells [1,2]. The pharmacokinetic
properties of these peptides are still to be explored.
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RESULTS & DISCUSSION 
Quorum sensing peptides are sufficiently stable in human plasma to exert biological functions. Moreover, they are able to cross the intestinal barrier and
thus can have a possible effect at distant sites of the body. Due to the permeability of some QSP through the blood-brain barrier, these peptides can even
affect the central nervous system and act as mediators of the gut-brain axis.
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CONCLUSIONS
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In vitro cell medium & human plasma stability
Peptide Sequence Cell medium half-life (hours) Human plasma half-life (minutes)
EDF-analogue NWN 42.03 268.2
PhrCACET1 SYPGWSW 9.89 23.6
BIP-2 GLWEDDLLYNINRYAHYIT 26.91 320.7
PhrANTH2 SKDYN 18.39 56.4
Methods: HPLC-UV and
UHPLC-PDA quantification
QSP are sufficiently stable in cell
medium and human plasma to exert
biological functions
BBB 
penetration
Methods: In vivo (mice)
multiple time regression
(MTR), efflux and capillary
depletion (CD).
Peptide (125I-) Kin (µl/g x min)
a
Initial brain distribution volume (µl/g)a
Parenchymal fraction (%) Capillary fraction (%) kout (min
-1)a
V0 (vascular) Vg (tissue)
BIP-2 2.68 ± 0.66 (6.59)b 18.22 ± 1.43 76.9 23.1 -0.06 ± 0.02
PhrCACET1 20.87 ± 7.97 (6.59)b 54.90 ± 5.75 84.9 15.1 -0.02 ± 0.04
PhrANTH2 0.18 ± 0.03 6.59 ± 0.47 NAc 79.4 20.6 -0.05 ± 0.07
a mean ± 1 standard error
b NA (V0): in the biphasic model, V0 was set to be equal to
the V0 of Phranth2 i.e. 6.59 µl/g
c NA (Vg): not applicable
Some QSP are able to cross the blood-brain barrier and
reach the brain parenchyma while no significant efflux
appears
 LINK WITH CENTRAL NERVOUS DISORDERS?
Intestinal 
permeability
Methods: Caco-2 
transport studies 
and HPLC/ESI-
MS quantification.
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Some QSP cross the intestinal barrier (Caco-2 cell)
and reach the blood circulation
 EFFECT AT DISTANT SITES OF THE BODY?
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